Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Aim of the FavorAx study is to evaluate preliminary efficacy and safety of Axitinib in
metastatic renal cell carcinoma patients with favorable IMDC prognostic factors who had
progressed on sunitinib or pazopanib in the first-line setting.